Search | Clinical Trials Finder

Conditions: Myotonic Dystrophy Type 1
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Myotonic Dystrophy Type 1 (DM1), DM1
Interventions: Not listed
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 88 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Myotonic Dystrophy
Interventions: Mexiletine, Placebo; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Breast Cancer
Interventions: Neratinib, T-DM1; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 15
States / cities: Weston, Florida • Decatur, Illinois • Effingham, Illinois + 7 more

Conditions: Breast Cancer, HER2-positive Breast Cancer
Interventions: trastuzumab-emtansine, Trastuzumab SC, Paclitaxel; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 53
States / cities: San Francisco, California • Derby, Connecticut • Fairfield, Connecticut + 44 more

Conditions: Breast Cancer Metastatic
Interventions: DZD1516 mono therapy in Part A, DZD1516 in combination with trastuzumab and/or capecitabine in Part B, DZD1516 in combination with T-DM1 in Part C; Drug
Lead sponsor: Dizal Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer
Interventions: Trastuzumab, Trastuzumab Emtansine (T-DM1), Pertuzumab, Tucatinib; Drug
Lead sponsor: Carey Anders, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 5 more

Conditions: Myotonic Dystrophy
Interventions: SomatoKine/IPLEX; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 21 Years to 60 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Myotonic Dystrophy 2
Interventions: Exercise; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Interventions: T-DM1, Capecitabine, External Beam Radiation Therapy 0, External Beam Radiation Therapy 1; Drug · Radiation
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Myotonic Dystrophy
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Myotonic Dystrophy Type 1, DM1, Myotonic Dystrophy, Myotonia, Myotonic Dystrophy 1, Myotonic Disorders, Steinert Myotonic Dystrophy, Steinert Disease
Interventions: Del-desiran (AOC 1001); Drug
Lead sponsor: Avidity Biosciences, Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 19
States / cities: Los Angeles, California • Stanford, California • Denver, Colorado + 16 more

Conditions: Metastatic Breast Cancer
Interventions: Trastuzumab emtansine [Kadcyla] 3.0 mg/kg, Trastuzumab emtansine [Kadcyla] 3.6 mg/kg, Pertuzumab 420 mg; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 10
States / cities: Boca Raton, Florida • Deerfield Beach, Florida • Maywood, Illinois + 6 more

Conditions: HER2-positive Breast Cancer, Breast Cancer Metastatic
Interventions: Palbociclib 75mg, Letrozole 2.5mg, T-DM1, Palbociclib 100mg, Palbociclib 125mg, Palbociclib; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 5
States / cities: Kansas City, Kansas • Overland Park, Kansas • Kansas City, Missouri + 1 more

Conditions: HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: PI3K inhibitor BYL719, ado-trastuzumab emtansine, pharmacological study, laboratory biomarker analysis; Drug · Biological · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Locally Advanced Cancer, Metastatic Cancer, HER2, HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, HER 2 Low-expressing Breast Cancer
Interventions: [68Ga]Ga-ABY-025; Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Myotonic Dystrophy Type 1
Interventions: IONIS-DMPKRx, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 8
States / cities: Stanford, California • Gainesville, Florida • Kansas City, Kansas + 5 more

Conditions: Myotonic Dystrophy, Type 1 (DM1), Myotonic Dystrophy
Interventions: ERX-963, Placebo; Drug
Lead sponsor: Expansion Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Palo Alto, California • Miami, Florida • Iowa City, Iowa + 1 more

Conditions: Myotonic Dystrophy 1, Excessive Daytime Sleepiness
Interventions: Pitolisant Oral Tablet, Placebo oral tablet; Drug
Lead sponsor: Harmony Biosciences Management, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 11
States / cities: Irvine, California • Aurora, Colorado • Tampa, Florida + 8 more

Conditions: HER2 Positive Breast Cancers
Interventions: Tucatinib (ONT-380), T-DM1; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 7
States / cities: Birmingham, Alabama • Aurora, Colorado • Kansas City, Kansas + 4 more

Conditions: Breast Cancer
Interventions: Trastuzumab emtansine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 15
States / cities: Fort Myers, Florida • Lafayette, Indiana • Scarborough, Maine + 11 more

Conditions: Breast Cancer
Interventions: docetaxel, paclitaxel, pertuzumab, pertuzumab-placebo, trastuzumab [Herceptin], trastuzumab emtansine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,095 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 62
States / cities: Little Rock, Arkansas • La Jolla, California • Montebello, California + 55 more

Conditions: Breast Cancer, Brain Metastasis, Brain Cancer
Interventions: T-DM1, TMZ; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Myotonic Dystrophy 1, DM1
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 10
States / cities: La Jolla, California • Los Angeles, California • Denver, Colorado + 7 more

Search by objective public record fields.

Cerebrospinal Fluid Biomarkers of Myotonic Dystrophy

Remote Assessments and Genetic Determinants of Myotonic Dystrophy

Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1

A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer

ATEMPT 2.0: Adjuvant T-DM1 vs TH

DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer

Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib

Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)

Investigating Exercise in Myotonic Dystrophy Type 2 (DM2)

Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer

Development of Quantitative Muscle Imaging as a Biomarker of Disease Endpoints in Myotonic Dystrophy

Global Open-Label Extension Study of Del-desiran for the Treatment of DM1

A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy

A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1

Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1

Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1

A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer

A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery

Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)